» Articles » PMID: 12466115

Craniopharyngiomas of Adamantinomatous Type Harbor Beta-catenin Gene Mutations

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2002 Dec 6
PMID 12466115
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Craniopharyngioma is a rare tumor occurring in the sellar region comprising 3% of all intracranial tumors. To elucidate the contribution of beta-catenin gene mutation to tumorigenesis, we examined genetic alterations and expression of beta-catenin in 10 cases of adamantinomatous and 6 cases of papillary craniopharyngiomas. Beta-catenin gene mutations were found in all of the adamantinomatous and none of the papillary craniopharyngiomas. Immunohistochemically, all cases of adamantinomatous craniopharyngioma showed cytoplasmic and nuclear expression of beta-catenin. In contrast, papillary craniopharyngiomas showed exclusively membranous expression. The results suggest that adamantinomatous- and papillary-type craniopharyngiomas are not only clinicopathologically, but also genetically, distinctive variants. Mutation of the beta-catenin gene therefore seems to play an important role in the tumorigenesis of adamantinomatous craniopharyngioma. Among the adamantinomatous-type tumors, beta-catenin-positive mesenchymal cells were observed in two cases. Microdissection-based mutational analysis revealed that these mesenchymal cells also harbor the same beta-catenin gene mutations as those of epithelial cells, suggesting their tumorous nature. Thus, at least a subset of adamantinomatous craniopharyngioma is considered to be biphasic.

Citing Articles

Targeted treatment for craniopharyngioma.

Stec N, Barker 2nd F, Brastianos P J Neurooncol. 2025; .

PMID: 39951179 DOI: 10.1007/s11060-025-04942-0.


Deciphering craniopharyngioma subtypes: Single-cell analysis of tumor microenvironment and immune networks.

Matsuda T, Kono T, Taki Y, Sakuma I, Fujimoto M, Hashimoto N iScience. 2024; 27(11):111068.

PMID: 39483146 PMC: 11525618. DOI: 10.1016/j.isci.2024.111068.


Insights into brain tumor diagnosis: exploring hybridization techniques.

Namiot E, Zembatov G, Tregub P Front Neurol. 2024; 15:1393572.

PMID: 39022728 PMC: 11252041. DOI: 10.3389/fneur.2024.1393572.


Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database.

Lehrich M, Tong C, Hsu P, Kuan C Childs Nerv Syst. 2024; 40(6):1661-1669.

PMID: 38421446 DOI: 10.1007/s00381-024-06320-z.


Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.

Gritsch D, Santagata S, Brastianos P Curr Treat Options Oncol. 2024; 25(2):261-273.

PMID: 38300480 PMC: 11203386. DOI: 10.1007/s11864-023-01156-2.


References
1.
Polakis P . Wnt signaling and cancer. Genes Dev. 2000; 14(15):1837-51. View

2.
Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M . Beta-catenin mutations in sporadic fundic gland polyps. Virchows Arch. 2002; 440(4):381-6. DOI: 10.1007/s004280100527. View

3.
Hurlstone A, Clevers H . T-cell factors: turn-ons and turn-offs. EMBO J. 2002; 21(10):2303-11. PMC: 126013. DOI: 10.1093/emboj/21.10.2303. View

4.
Giangaspero F, Burger P, Osborne D, Stein R . Suprasellar papillary squamous epithelioma ("papillary craniopharyngioma"). Am J Surg Pathol. 1984; 8(1):57-64. DOI: 10.1097/00000478-198401000-00006. View

5.
Kajino Y, Yamaguchi A, Hashimoto N, Matsuura A, Sato N, Kikuchi K . beta-Catenin gene mutation in human hair follicle-related tumors. Pathol Int. 2001; 51(7):543-8. DOI: 10.1046/j.1440-1827.2001.01231.x. View